Skip to content
Screener

MaxCyte MXCT Q3 2025 earnings

Reported November 12, 2025 · After market close

Revenue$6.8MMiss by $2.6M
EPS-$0.12Miss by $0.01
Revenue estimate$9.4M
EPS estimate-$0.11

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$7.0M
EPS estimate-$0.08

Financials

Q3 2025

Income statement

See full
Revenue$6.8M-16.4%
Gross profit$5.2M-16.1%
Operating income-$14.1M-0.7%
Net income-$12.4M-7.4%
EPS (diluted)-$0.12-9.1%

Balance sheet

See full
Cash & equivalents$13.0M-64.9%
Total debt$18.2M-0.9%
Total equity$180.3M-15.5%
Total assets$213.5M-14.1%

Cash flow

See full
Operating cash flow-$7.5M-69.8%
CapEx$300.0K-26.1%
Free cash flow-$7.8M-61.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$168.44M-58.6%
Enterprise value$173.63M-55.3%
P/S4.9×-4.0×

Profitability

See full
Gross margin80%-6.0pp
Operating margin-155.6%+175pp
Net margin-132.6%+297pp
FCF margin-119.8%-332pp

Returns & leverage

See full
Return on equity-23.2%+18.9pp
Debt / equity0.1×0.0×
Current ratio7.7×-2.1×

Segments

By product

See full
License$2.2M—
Assay And Other Service Revenue$650.0K—

By segment

See full
Cell Engineering Technology$6.8M-16.4%

FAQ

When did MaxCyte report Q3 2025 earnings?
MaxCyte (MXCT) reported Q3 2025 earnings on November 12, 2025 after market close.
What were MaxCyte's Q3 2025 revenue and EPS?
MaxCyte reported revenue of $6.8M and eps of $-0.12 for Q3 2025.
Did MaxCyte beat estimates in Q3 2025?
Revenue missed the consensus estimate of $9.4M by $2.6M. EPS missed the consensus estimate of $-0.11 by $0.01.
How did MaxCyte's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 16.4% from $8.2M a year earlier and eps declined 9.1% from $-0.11.
Where can I find MaxCyte's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-110375) and the 10-Q periodic report (0001104659-25-111396) directly on SEC EDGAR. The filing index links above go to sec.gov.